Researchers have categorized samples into high-expression and low-expression groups on the basis of the number of TLSs observed in the field among NSCLC patients receiving neoadjuvant anti-PD-1/PD-L1 therapy combined with chemotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.